Role of the VEGF/VEGFR Axis in Cancer Biology and Therapy

Advances in Cancer Research

Volumn 114, Issue , 2012, Pages 237-267

  Rapisarda, Annamaria ^a   Melillo, Giovanni ^b  

^a SAIC FREDERICK INC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anti angiogenic therapy; Biomarkers; Hypoxia; Resistance; VEGF; VEGFR

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; AE 941; AFLIBERCEPT; ALACIZUMAB PEGOL; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BORTEZOMIB; BRIVANIB ALANINATE; CABOZANTINIB; CEDIRANIB; CRIZOTINIB; EVEROLIMUS; FIRTECAN PEGOL; FLUOROURACIL; FORETINIB; IMV 1121 B; IRINOTECAN; LONIDAMINE; MF 1; PAZOPANIB; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIRAPAZAMINE; TIVOZANIB; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ANTIANGIOGENIC THERAPY; ARTICLE; ASTROCYTOMA; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; HYPOXIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

EID: 84860792754     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386503-8.00006-5     Document Type: Chapter

References (162)

1. Achen M.G., Stacker S.A. Targeting tumor stroma. Curr. Cancer Drug Targets 2008, 8:446.
2. Albuquerque R.J.C., Hayashi T., Cho W.G., Kleinman M.E., Dridi S., Takeda A., Baffi J.Z., Yamada K., Kaneko H., Green M.G., Chappell J., Wilting J., et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat. Med. 2009, 15:1023-1030.
3. Batchelor T.T., Sorensen A.G., di T.E., Zhang W.T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., Ancukiewicz M., Mrugala M.M., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
4. Becker J., Pavlakovic H., Ludewig F., Wilting F., Weich H.A., Albuquerque R., Ambati J., Wilting J. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2. Clin. Cancer Res. 2010, 16:1431-1441.
5. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 1999, 103:159-165.
6. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
7. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111:1287-1295.
8. Bertolini F., Shaked Y., Mancuso P., Kerbel R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 2006, 6:835-845.
9. Bertolini F., Mancuso P., Shaked Y., Kerbel R.S. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov. Today 2007, 12:806-812.
10. Bocci G., Man S., Green S.K., Francia G., Ebos J.M., du Manoir J.M., Weinerman A., Emmenegger U., Ma L., Thorpe P., Davidoff A., Huber J., et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 2004, 64:6616-6625.
11. Bottaro D.P., Liotta L.A. Cancer: out of air is not out of action. Nature 2003, 423:593-595.
12. Bruns C.J., Shrader M., Harbison M.T., Portera C., Solorzano C.C., Jauch K.W., Hicklin D.J., Radinsky R., Ellis L.M. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int. J. Cancer 2002, 102:101-108.
13. Burris H., Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 2008, 13:289-298.
14. Calvani M., Rapisarda A., Uranchimeg B., Shoemaker R.H., Melillo G. Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 2006, 107:2705-2712.
15. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
16. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
17. Carmeliet P., De Smet F., Loges S., Mazzone M. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat. Rev. Clin. Oncol. 2009, 6:315-326.
18. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
19. Cascone T., Herynk M.H., Xu L., Du Z., Kadara H., Nilsson M.B., Oborn C.J., Park Y.Y., Erez B., Jacoby J., Lee J.S., Lin H.Y., et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J. Clin. Invest. 2011, 121:1313-1328.
20. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., Capla J.M., Galiano R.D., Levine J.P., Gurtner G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 2004, 10:858-864.
21. Chen W., Delaloye S., Silverman D.H., Geist C., Czernin J., Sayre J., Satyamurthy N., Pope W., Lai A., Phelps M.E., Cloughesy T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 2007, 25:4714-4721.
22. Chiche J., Ilc K., Laferriere J., Trottier E., Dayan F., Mazure N.M., Brahimi-Horn M.C., Pouyssegur J. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 2009, 69:358-368.
23. Chiche J., Brahimi-Horn M.C., Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J. Cell. Mol. Med. 2010, 14:771-794.
24. Ciardiello F., Bianco R., Caputo R., Caputo R., Damiano V., Troiani T., Melisi D., De Vita F., De Placido S., Bianco A.R., Tortora G. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin. Cancer Res. 2004, 10:784-793.
25. Cohen T., Herzog Y., Brodzky A., Greenson J.K., Eldar S., Gluzman-Poltorak Z., Neufeld G., Resnick M.B. Neuropilin-2 is a novel marker expressed in pancreatic islet cells and endocrine pancreatic tumours. J. Pathol. 2002, 198:77-82.
26. Conley S.J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A.N., Clouthier S.G., Wicha M.S. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. USA 2012, 109(8):2784-2789.
27. Crawford Y., Kasman I., Yu L., Zhong C., Wu X., Modrusan Z., Kaminker J., Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009, 15:21-34.
28. Dang D.T., Chun S.Y., Burkitt K., Abe M., Chen S., Havre P., Mabjeesh N.J., Heath E.I., Vogelzang N.J., Cruz-Correa M., Blayney D.W., Ensminger W.D., et al. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. Cancer Res. 2008, 68:1872-1880.
29. de Bazelaire C., Alsop D.C., George D., Pedrosa I., Wang Y., Michaelson M.D., Rofsky N.M. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin. Cancer Res. 2008, 14:5548-5554.
30. De Luca A., Normanno N. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. IDrugs 2010, 13:636-645.
31. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., McArthur G., Judson I.R., Heinrich M.C., Morgan J.A., Desai J., Fletcher C.D., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
32. Denko N.C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 2008, 8:705-713.
33. Diaz-Padilla I., Siu L.L. Brivanib alaninate for cancer. Expert Opin. Investig. Drugs 2011, 20:577-586.
34. Diez H., Fischer A., Winkler A., Hu C.J., Hatzopoulos A.K., Breier G., Gessler M. Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp. Cell Res. 2007, 313:1-9.
35. DiSalvo J., Bayne M.L., Conn G., Kwok P.W., Trivedi P.G., Soderman D.D., Palisi T.M., Sullivan K.A., Thomas K.A. Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. J. Biol. Chem. 1995, 270:7717-7723.
36. Dowlati A., Gray R., Sandler A.B., Schiller J.H., Johnson D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an eastern cooperative oncology group study. Clin. Cancer Res. 2008, 14:1407-1412.
37. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
38. Ellis L.M., Hicklin D.J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin. Cancer Res. 2008, 14:6371-6375.
39. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8:579-591.
40. Ellis L.M., Liu W., Wilson M. Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation. Surgery 1996, 120:871-878.
41. Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., Le Q.T., Giaccia A.J. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15:35-44.
42. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S.p., Siebels M., Negrier S., Chevreau C., Solska E., Desai A.A., Rolland F.d.r., Demkow T., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356:125-134.
43. Escudier B., Bellmunt J., Negrier S., Bajetta E., Melichar B., Bracarda S., Ravaud A., Golding S., Jethwa S., Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 2010, 28:2144-2150.
44. Failla C.M., Odorisio T., Cianfarani F., Schietroma C., Puddu P., Zambruno G. Placenta growth factor is induced in human keratinocytes during wound healing. J. Invest. Dermatol. 2000, 115:388-395.
45. Fan F., Wey J.S., McCarty M.F., Belcheva A., Liu W., Bauer T.W., Somcio R.J., Wu Y., Hooper A., Hicklin D.J., Ellis L.M. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005, 24:2647-2653.
46. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005, 69(Suppl 3):11-16.
47. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18:4-25.
48. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
49. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De M.M., Autiero M., Wyns S., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
50. Franco M., Man S., Chen L., Emmenegger U., Shaked Y., Cheung A.M., Brown A.S., Hicklin D.J., Foster F.S., Kerbel R.S. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res. 2006, 66:3639-3648.
51. Friedman H.S., Prados M.D., Wen P.Y., Mikkelsen T., Schiff D., Abrey L.E., Yung W.K.A., Paleologos N., Nicholas M.K., Jensen R., Vredenburgh J., Huang J., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009, 27:4733-4740.
52. Gerber H.P., Kowalski J., Sherman D., Eberhard D.A., Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 2000, 60:6253-6258.
53. Gille H., Kowalski J., Yu L., Chen H., Pisabarro M.T., Davis-Smyth T., Ferrara N. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration. EMBO J. 2000, 19:4064-4073.
54. Gille J., Heidenreich R., Pinter A., Schmitz J., Boehme B., Hicklin D.J., Henschler R., Breier G. Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation. Int. J. Cancer 2007, 120:1899-1908.
55. Green C.J., Lichtlen P., Huynh N.T., Yanovsky M., Laderoute K.R., Schaffner W., Murphy B.J. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res. 2001, 61:2696-2703.
56. Greenberg J.I., Shields D.J., Barillas S.G., Acevedo L.M., Murphy E., Huang J., Scheppke L., Stockmann C., Johnson R.S., Angle N., Cheresh D.A. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456:809-813.
57. Haiko P., Makinen T., Keskitalo S., Taipale J., Karkkainen M.J., Baldwin M.E., Stacker S.A., Achen M.G., Alitalo K. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol. Cell. Biol. 2008, 28:4843-4850.
58. Hansel D.E., Wilentz R.E., Yeo C.J., Schulick R.D., Montgomery E., Maitra A. Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract. Am. J. Surg. Pathol. 2004, 28:347-356.
59. He Y., Rajantie I., Ilmonen M., Makinen T., Karkkainen M.J., Haiko P., Salven P., Alitalo K. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res. 2004, 64:3737-3740.
60. He Y., Rajantie I., Pajusola K., Jeltsch M., Holopainen T., Yla-Herttuala S., Harding T., Jooss K., Takahashi T., Alitalo K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005, 65:4739-4746.
61. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 23:1011-1027.
62. Hirota K., Semenza G.L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 2006, 59:15-26.
63. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
64. Jain R.K. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 2005, 19:7-16.
65. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
66. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006, 3:24-40.
67. Karjalainen K., Jaalouk D.E., Bueso-Ramos C.E., Zurita A.J., Kuniyasu A., Eckhardt B.L., Marini F.C., Lichtiger B., O'Brien S., Kantarjian H.M., Cortes J.E., Koivunen E., et al. Targeting neuropilin-1 in human leukemia and lymphoma. Blood 2011, 117:920-927.
68. Kawakami T., Tokunaga T., Hatanaka H., Kijima H., Yamazaki H., Abe Y., Osamura Y., Inoue H., Ueyama Y., Nakamura M. Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer 2002, 95:2196-2201.
69. Kelly R.J., Darnell C., Rixe O. Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity. Cancer J. 2010, 16:635-642.
70. Kendall R.L., Wang G., DiSalvo J., Thomas K.A. Specificity of vascular endothelial cell growth factor receptor ligand binding domains. Biochem. Biophys. Res. Commun. 1994, 201:326-330.
71. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358:2039-2049.
72. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2002, 2:727-739.
73. Keunen O., Johansson M., Oudin A., Sanzey M., Rahim S.A., Fack F., Thorsen F., Taxt T., Bartos M., Jirik R., Miletic H., Wang J., et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl. Acad. Sci. USA 2011, 108:3749-3754.
74. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
75. Kim J.J., Vaziri S.A.J., Rini B.I., Elson P., Garcia J.A., Wirka R., Dreicer R., Ganapathi M.K., Ganapathi R. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012, 118(7):1946-1954.
76. Klohs W.D., Hamby J.M. Antiangiogenic agents. Curr. Opin. Biotechnol. 1999, 10:544-549.
77. Kreisl T.N., Kim L., Moore K., Duic P., Royce C., Stroud I., Garren N., Mackey M., Butman J.A., Camphausen K., Park J., Albert P.S., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 2009, 27:740-745.
78. Laakkonen P., Waltari M., Holopainen T., Takahashi T., Pytowski B., Steiner P., Hicklin D., Persaud K., Tonra J.R., Witte L., Alitalo K. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 2007, 67:593-599.
79. Lantuejoul S., Constantin B., Drabkin H., Brambilla C., Roche J., Brambilla E. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J. Pathol. 2003, 200:336-347.
80. Larcher F., Franco M., Bolontrade M., Rodriguez-Puebla M., Casanova L., Navarro M., Yancopoulos G., Jorcano J.L., Conti C.J. Modulation of the angiogenesis response through Ha-ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis. Mol. Carcinog. 2003, 37:83-90.
81. Latil A., Bieche I., Pesche S., Valeri A., Fournier G., Cussenot O., Lidereau R. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int. J. Cancer 2000, 89:167-171.
82. Lesslie D.P., Summy J.M., Parikh N.U., Fan F., Trevino J.G., Sawyer T.K., Metcalf C.A., Shakespeare W.C., Hicklin D.J., Ellis L.M., Gallick G.E. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br. J. Cancer 2006, 94:1710-1717.
83. Levine A.M., Tulpule A., Quinn D.I., Gorospe G., Smith D.L., Hornor L., Boswell W.D., Espina B.M., Groshen S.G., Masood R., Gill P.S. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J. Clin. Oncol. 2006, 24:1712-1719.
84. Li B., Sharpe E.E., Maupin A.B., Teleron A.A., Pyle A.L., Carmeliet P., Young P.P. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J. 2006, 20:1495-1497.
85. Li J.L., Sainson R.C., Oon C.E., Turley H., Leek R., Sheldon H., Bridges E., Shi W., Snell C., Bowden E.T., Wu H., Chowdhury P.S., et al. DLL4-notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011, 71:6073-6083.
86. Liang W.C., Wu X., Peale F.V., Lee C.V., Meng Y.G., Gutierrez J., Fu L., Malik A.K., Gerber H.P., Ferrara N., Fuh G. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 2006, 281:951-961.
87. Lindsay C.R., MacPherson I.R., Cassidy J. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncol. 2009, 5:421-432.
88. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390.
89. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., Yao V.J., Inai T., Brooks P., Freimark B., Shalinsky D.R., Hu-Lowe D.D., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 2006, 116:2610-2621.
90. McColl B.K., Baldwin M.E., Roufail S., Freeman C., Moritz R.L., Simpson R.J., Alitalo K., Stacker S.A., Achen M.G. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J. Exp. Med. 2003, 198:863-868.
91. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol. Cancer Res. 2006, 4:601-605.
92. Morabito A., Piccirillo M.C., Falasconi F., De Feo G., Del Giudice A., Bryce J., Di Maio M., De Maio E., Normanno N., Perrone F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009, 14:378-390.
93. Motzer R.J., Michaelson M.D., Rosenberg J., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., Redman B.G., Margolin K.A., Wilding G. Sunitinib efficacy against advanced renal cell carcinoma. J. Urol. 2007, 178:1883-1887.
94. Muramatsu M., Yamamoto S., Osawa T., Shibuya M. Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth. Cancer Res. 2010, 70:8211-8221.
95. Murukesh N., Dive C., Jayson G.C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer 2010, 102:8-18.
96. Mylona E., Alexandrou P., Giannopoulou I., Liapis G., Sofia M., Keramopoulos A., Nakopoulou L. The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma. Gynecol. Oncol. 2007, 104:557-563.
97. Narayana A., Kelly P., Golfinos J., Parker E., Johnson G., Knopp E., Zagzag D., Fischer I., Raza S., Medabalmi P., Eagan P., Gruber M.L. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 2009, 110:173-180.
98. Narayana A., Gruber D., Kunnakkat S., Golfinos J.G., Parker E., Raza S., Zagzag D., Eagan P., Gruber M.L. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J. Neurosurg. 2011, 116:341-345.
99. Norden A.D., Young G.S., Setayesh K., Muzikansky A., Klufas R., Ross G.L., Ciampa A.S., Ebbeling L.G., Levy B., Drappatz J., Kesari S., Wen P.Y. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70:779-787.
100. Nowak D.G., Woolard J., Amin E.M., Konopatskaya O., Saleem M.A., Churchill A.J., Ladomery M.R., Harper S.J., Bates D.O. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J. Cell Sci. 2008, 121:3487-3495.
101. Olcina M., Lecane P.S., Hammond E.M. Targeting hypoxic cells through the DNA damage response. Clin. Cancer Res. 2010, 16:5624-5629.
102. Onnis B., Rapisarda A., Melillo G. Development of HIF-1 inhibitors for cancer therapy. J. Cell. Mol. Med. 2009, 13:2780-2786.
103. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
104. Pan Q., Chathery Y., Wu Y., Rathore N., Tong R.K., Peale F., Bagri A., Tessier-Lavigne M., Koch A.W., Watts R.J. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J. Biol. Chem. 2007, 282:24049-24056.
105. Papandreou I., Goliasova T., Denko N.C. Anticancer drugs that target metabolism: is dichloroacetate the new paradigm?. Int. J. Cancer 2011, 128:1001-1008.
106. Paule B., Bastien L., Deslandes E., Cussenot O., Podgorniak M.P., Allory Y., Nami B., Porcher R., de La Taille A., Menashi S., Calvo F., Mourah S. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One 2010, 5:e10715.
107. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
108. Petrova T.V., Bono P., Holnthoner W., Chesnes J., Pytowski B., Sihto H., Laakkonen P., Heikkila P., Joensuu H., Alitalo K. VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell 2008, 13:554-556.
109. Podar K., Anderson K.C. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005, 105:1383-1395.
110. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., Overholser J., Hooper A., Pytowski B., Witte L., Bohlen P., Hicklin D.J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999, 59:5209-5218.
111. Rapisarda A., Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist. Updat. 2009, 12:74-80.
112. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004, 64:1475-1482.
113. Rapisarda A., Zalek J., Hollingshead M., Braunschweig T., Uranchimeg B., Bonomi C.A., Borgel S.D., Carter J.P., Hewitt S.M., Shoemaker R.H., Melillo G. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 2004, 64:6845-6848.
114. Rapisarda A., Hollingshead M., Uranchimeg B., Bonomi C.A., Borgel S.D., Carter J.P., Gehrs B., Raffeld M., Kinders R.J., Parchment R., Anver M.R., Shoemaker R.H., et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol. Cancer Ther. 2009, 8:1867-1877.
115. Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., Valle J., Metrakos P., Smith D., Vinik A., Chen J.S., Horsch D., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011, 364:501-513.
116. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., Harris A.L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997, 57:963-969.
117. Rini B.I., Halabi S., Rosenberg J.E., Stadler W.M., Vaena D.A., Ou S.S., Archer L., Atkins J.N., Picus J., Czaykowski P., Dutcher J., Small E.J. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 2008, 26:5422-5428.
118. Rohrberg K.S., Pappot H., Lassen U., Westman M., Olesen R.K., Pfeiffer P., Ladekarl M., Srensen M., Christensen I.J., Skov B.G. Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab. Cancer Biol. Ther. 2011, 11:732-739.
119. Rouschop K.M., Wouters B.G. Regulation of autophagy through multiple independent hypoxic signaling pathways. Curr. Mol. Med. 2009, 9:417-424.
120. Saif M.W. Pancreatic cancer: are we moving forward yet? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 20th, 2007. JOP 2007, 8:166-176.
121. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355:2542-2550.
122. Sathornsumetee S., Cao Y., Marcello J.E., Herndon J.E., McLendon R.E., Desjardins A., Friedman H.S., Dewhirst M.W., Vredenburgh J.J., Rich J.N. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 2008, 26:271-278.
123. Scheufler K.M., Drevs J., van V.V., Reusch P., Klisch J., Augustin H.G., Zentner J., Marme D. Implications of vascular endothelial growth factor, sFlt-1, and sTie-2 in plasma, serum and cerebrospinal fluid during cerebral ischemia in man. J. Cereb. Blood Flow Metab. 2003, 23:99-110.
124. Schneider B.P., Wang M., Radovich M., Sledge G.W., Badve S., Thor A., Flockhart D.A., Hancock B., Davidson N., Gralow J., Dickler M., Perez E.A., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 2008, 26:4672-4678.
125. Scott E.N., Meinhardt G., Jacques C., Laurent D., Thomas A.L. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin. Investig. Drugs 2007, 16:367-379.
126. Seto T., Higashiyama M., Funai H., Imamura F., Uematsu K., Seki N., Eguchi K., Yamanaka T., Ichinose Y. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 2006, 53:91-96.
127. Shaheen R.M., Tseng W.W., Vellagas R., Liu W., Ahmad S.A., Jung Y.D., Reinmuth N., Drazan K.E., Bucana C.D., Hicklin D.J., Ellis L.M. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int. J. Oncol. 2001, 18:221-226.
128. Shaked Y., Ciarrocchi A., Franco M., Lee C.R., Man S., Cheung A.M., Hicklin D.J., Chaplin D., Foster F.S., Benezra R., Kerbel R.S. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313:1785-1787.
129. Shibuya M., Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 2006, 312:549-560.
130. Shojaei F., Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res. 2008, 68:5501-5504.
131. Shojaei F., Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist. Updat. 2008, 11:219-230.
132. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007, 25:911-920.
133. Smit E.F., Lubberink M., Bahce I., Walraven M., de Boer M.P., Greuter H.N., Hendrikse N.H., Eriksson J., Windhorst A.D., Postmus P.E., Verheul H.M., Serne E.H., et al. Effects of the antiangiogenic drug bevacizumab on tumor perfusion and drug delivery of 11C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): implications for scheduling of antiangiogenic agents. ASCO Meeting Abstr. 2011, 29:3059.
134. Smith N.R., Baker D., James N.H., Ratcliffe K., Jenkins M., Ashton S.E., Sproat G., Swann R., Gray N., Ryan A., Jrgensmeier J.M., Womack C. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin. Cancer Res. 2010, 16:3548-3561.
135. Spratlin J. Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr. Oncol. Rep. 2011, 13:97-102.
136. Steeg P.S. Angiogenesis inhibitors: motivators of metastasis?. Nat. Med. 2003, 9:822-823.
137. Stephenson J.M., Banerjee S., Saxena N.K., Cherian R., Banerjee S.K. Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: a possible marker for the progression of breast cancer. Int. J. Cancer 2002, 101:409-414.
138. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C.H., Salman P., Gladkov O.A., Kavina A., Zarba J.J., Chen M., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 2010, 28:1061-1068.
139. Sulkes A. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as paradigm. Israel Med. Assoc. J. 2010, 12:628-632.
140. Teng L.S., Jin K.T., He K.F., Zhang J., Wang H.H., Cao J. Clinical applications of VEGF-Trap (Aflibercept) in cancer treatment. J. Chin. Med. Assoc. 2010, 73:449-456.
141. Toi M., Bando H., Ogawa T., Muta M., Hornig C., Weich H.A. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int. J. Cancer 2002, 98:14-18.
142. Ton N.C., Parker G.J.M., Jackson A., Mullamitha S., Buonaccorsi G.A., Roberts C., Watson Y., Davies K., Cheung S., Hope L., Power F., Lawrance J., et al. Phase I evaluation of CDP791, a PEGylated Di-Fab conjugate that binds vascular endothelial growth factor receptor 2. Clin. Cancer Res. 2007, 13:7113-7118.
143. Van Meter M.E., Kim E.S. Bevacizumab: current updates in treatment. Curr. Opin. Oncol. 2010, 22:586-591.
144. Vanveldhuizen P.J., Zulfiqar M., Banerjee S., Cherian R., Saxena N.K., Rabe A., Thrasher J.B., Banerjee S.K. Differential expression of neuropilin-1 in malignant and benign prostatic stromal tissue. Oncol. Rep. 2003, 10:1067-1071.
145. Vredenburgh J.J., Desjardins A., Herndon J.E., Marcello J., Reardon D.A., Quinn J.A., Rich J.N., Sathornsumetee S., Gururangan S., Sampson J., Wagner M., Bailey L., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 2007, 25:4722-4729.
146. Waldner M.J., Wirtz S., Jefremow A., Warntjen M., Neufert C., Atreya R., Becker C., Weigmann B., Vieth M., Rose-John S., Neurath M.F. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J. Exp. Med. 2010, 207:2855-2868.
147. Wedam S.B., Low J.A., Yang S.X., Chow C.K., Choyke P., Danforth D., Hewitt S.M., Berman A., Steinberg S.M., Liewehr D.J., Plehn J., Doshi A., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 2006, 24:769-777.
148. Wedge S.R., Ogilvie D.J., Dukes M., Kendrew J., Chester R., Jackson J.A., Boffey S.J., Valentine P.J., Curwen J.O., Musgrove H.L., Graham G.A., Hughes G.D., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002, 62:4645-4655.
149. White J. The challenge of rational development of complex natural products as cancer therapeutics. J. Natl. Cancer Inst. 2010, 102:834-835.
150. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11:393-410.
151. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di T.E., Munn L.L., Jain R.K. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
152. Wouters B.G., Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 2008, 8:851-864.
153. Wu Y., Hooper A.T., Zhong Z., Witte L., Bohlen P., Rafii S., Hicklin D.J. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int. J. Cancer 2006, 119:1519-1529.
154. Wu Y., Zhong Z., Huber J., Bassi R., Finnerty B., Corcoran E., Li H., Navarro E., Balderes P., Jimenez X., Koo H., Mangalampalli V.R.M., et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin. Cancer Res. 2006, 12:6573-6584.
155. Xian X., Hakansson J., Stahlberg A., Lindblom P., Betsholtz C., Gerhardt H., Semb H. Pericytes limit tumor cell metastasis. J. Clin. Invest. 2006, 116:642-651.
156. Yan M., Plowman G.D. Delta-like 4/Notch signaling and its therapeutic implications. Clin. Cancer Res. 2007, 13:7243-7246.
157. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349:427-434.
158. Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., Carbone D.P., Matrisian L.M., Richmond A., Lin P.C., Moses H.L. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35.
159. Yopp A.C., Schwartz L.H., Kemeny N., Gultekin D.H., Gonen M., Bamboat Z., Shia J., Haviland D., D'Angelica M.I., Fong Y., DeMatteo R.P., Allen P.J., et al. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann. Surg. Oncol. 2011, 18:2192-2199.
160. You W.K., Sennino B., Williamson C.W., Falcon B., Hashizume H., Yao L.C., Aftab D.T., McDonald D.M. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011, 71:4758-4768.
161. Youssoufian H., Hicklin D.J., Rowinsky E.K. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin. Cancer Res. 2007, 13:5544s-5548s.
162. Zhu Z., Lu D., Kotanides H., Santiago A., Jimenez X., Simcox T., Hicklin D.J., Bohlen P., Witte L. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Lett. 1999, 136:203-213.